47 results about "Hepatocyte Growth Factor Receptor" patented technology

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

General formula (I) (wherein, R 1 It is a 3- to 10-membered non-aromatic heterocyclic group or the like. R 2 and R 3 for a hydrogen atom. R 4 , R 5 , R 6 and R 7 Same or different, hydrogen atom, halogen atom, C 1－6 Alkyl etc. R 8 for hydrogen atoms, etc. R 9 It is a 3- to 10-membered non-aromatic heterocyclic group or the like. n is an integer of 1-2. X is a group represented by the formula -CH= or a nitrogen atom. ) or their salts or their hydrates have excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibit antitumor activity, angiogenesis inhibitory activity or cancer metastasis inhibitory activity.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.

The invention relates to biocatalytic methods for preparing enantiomerically pure stereoisomers of 1-(2,6-dichloro-3-fluorophenyl)ethanol. Disclosed are methods of preparation of the desired (S)-enantiomer, which methods are based on a combination of enzymatic resolution, chemical esterification and chemical hydrolysis with inversion of 1-(2,6-dichloro-3-fluorophenyl)ethyl esters or stereoselective bio-reduction of 2,6-dichloro-3-fluoro-acetophenone with a biocatalyst such as an enzyme or a microorganism. The chiral (S)-enantiomer can be used in the synthesis of certain enantiomerically enriched, ether linked 2-aminopyridine compounds that potently inhibit auto-phosphorylation of human heptocyte growth factor receptor.

The present invention provides the use of a fungal immunomodulatory protein (FIP) in manufacturing a medicament for inhibiting hepatocyte growth factor receptor (HGFR) activity in a cell, and for treating HGFR-associated cancer.

Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

The present invention provides a combination of anti-HGF / SF antibodies that specifically bind HGF / SF and inhibits HGF / SF activity. The present invention further provides a combination of anti-HGF / SF antibodies comprising three or more anti-HGF / SF antibodies selected from the group consisting of: antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF / SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer.

A therapeutic agent for rheumatoid arthritis, particularly a therapeutic agent for ameliorating an inflammatory symptom or bone deformity in rheumatoid arthritis, which comprises an antibody that binds to a hepatocyte growth factor receptor as an active ingredient.

The invention relates to a medicament composition containing a histone deacetylases (HDAC) inhibitor, a hepatocyte growth factor receptor (cMet) inhibitor, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and application thereof in preparing the medicaments for treating liver cancer, lung cancer, colon cancer, kidney cancer, gastric cancer, brain tumor, sarcoma, pancreatic cancer, ovarian cancer, breast cancer or prostatic cancer. The medicament composition has the obvious synergistic effect, improves the curative efficiency of the medicaments, decreases the drug dosage and reduces the occurrence frequency of the side-effect.

Novel polypeptides that are splice variants of c-Met, the receptor for hepatocyte growth factor and polynucleotides encoding same are provided. Methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention, are also provided.

The present invention provides the use of a fungal immunomodulatory protein (FIP) in manufacturing a medicament for inhibiting hepatocyte growth factor receptor (HGFR) activity in a cell, and for treating HGFR-associated cancer.

The invention relates to a hepatocyte growth factor receptor key structural domain fusion protein and an application thereof. The fusion protein comprises an epidermal growth factor receptor strong signal peptide, a hepatocyte growth factor receptor key structural domain and a His tag. The fusion protein is used for the preparation of an antibody. The hepatocyte growth factor receptor key structural domain fusion protein is stably expressed by a lentiviral vector in 293T cells in a long-acting manner and can be specifically bound with the hepatocyte growth factor. The fusion protein has an important role in research and development on neutralizing antibody drugs for screening and blocking a C-Met / HGF signal transduction pathway to further inhibit tumor growth.

The invention especially relates to a radioactive C-MET-targeted affinity micromolecular compound and application thereof, belonging to the field of medical diagnosis and treatment. According to the invention, in-vivo tracking and imaging of diseases like tumors is realized through radiolabeling of a C-MET receptor antagonist. The radioactive C-MET-targeted affinity micromolecular compound can be used for monitoring the characteristics of biochemical changes of a hepatocyte growth factor receptor, visually displays the distribution and quantity of C-MET and is applicable to specific detection of a plurality of cancers including glioma, lung cancer, prostatic cancer, breast cancer, esophagus cancer, stomach cancer, liver cancer, pancreas cancer, ovarian cancer, rectal cancer and cervical cancer. The radioactive C-MET-targeted affinity micromolecular compound also has certain anticancer activity and has wide clinical application prospect.

The invention discloses a use for screening and developing a medicine effectively useful in the pharmacologia by encoding or containing polynucleotide or polypeptide in at least IPT-3 and IPT-4 structure domain outside the receptor cell of the hepatocyte growth factor, and preferably for treating cancer caused by hepatocyte growth factor receptor misadjusting.